We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ayala Pharmaceuticals Inc (QX) | USOTC:ADXS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0245 | 4.62% | 0.555 | 0.55 | 0.6491 | 0.56 | 0.535 | 0.535 | 1,601 | 17:33:48 |
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results for the three months ended January 31, 2018, to take place on Monday, March 12, 2018.
Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 4:30 p.m. Eastern time on Monday, March 12, 2018.
Conference Call & Webcast InformationWHEN: Monday, March 12, 2018 at 4:30 p.m. Eastern time.DOMESTIC DIAL-IN: (844) 348-6133INTERNATIONAL DIAL-IN: (631) 485-4564CONFERENCE ID: 2588455WEBCAST: ir.advaxis.com/events-presentations
For those unable to participate in the live conference call or webcast, a digital recording will be available beginning March 12, 2018 two hours after the close of the conference call. To access the recording, dial (855) 859-2056 or (404) 537-3406 and provide the operator with the conference ID: 2588455. In addition, the audio webcast will be archived on the Company’s website for a period of time at ir.advaxis.com/events-presentations/events-calendar.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains integrate multiple functions into a single immunotherapy, and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and near-clinical development: HPV-associated cancers, individualized neoantigen immunotherapy, cancer-specific hotspot mutation immunotherapies and prostate cancer.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180309005131/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr. Director Corporate Communications and Government AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach, 908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA Investor RelationsAnne Marie Fields, 212-838-3777afields@lhai.com
1 Year Ayala Pharmaceuticals (QX) Chart |
1 Month Ayala Pharmaceuticals (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions